Apellis Pharmaceuticals (NASDAQ:APLS) Stock Rating Reaffirmed by Robert W. Baird

Robert W. Baird restated their outperform rating on shares of Apellis Pharmaceuticals (NASDAQ:APLS) in a research note published on Friday, Benzinga reports. They currently have a $100.00 price target on the stock.

APLS has been the subject of several other research reports. Mizuho decreased their price objective on Apellis Pharmaceuticals from $60.00 to $52.00 and set a neutral rating for the company in a report on Monday, April 29th. JPMorgan Chase & Co. boosted their price objective on Apellis Pharmaceuticals from $78.00 to $79.00 and gave the company an overweight rating in a report on Wednesday, March 6th. UBS Group decreased their price objective on Apellis Pharmaceuticals from $89.00 to $85.00 and set a buy rating for the company in a report on Wednesday, May 8th. HC Wainwright restated a buy rating and set a $92.00 price objective on shares of Apellis Pharmaceuticals in a report on Tuesday, May 28th. Finally, Wedbush decreased their price objective on Apellis Pharmaceuticals from $67.00 to $57.00 and set a neutral rating for the company in a report on Wednesday, April 17th. Four research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of Moderate Buy and a consensus price target of $75.56.

Apellis Pharmaceuticals Price Performance

Shares of APLS opened at $36.29 on Friday. Apellis Pharmaceuticals has a 52-week low of $19.83 and a 52-week high of $91.35. The company has a debt-to-equity ratio of 0.35, a quick ratio of 3.02 and a current ratio of 3.77. The business’s 50 day moving average price is $42.37 and its two-hundred day moving average price is $54.60. The firm has a market cap of $4.40 billion, a PE ratio of -10.49 and a beta of 0.95.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings results on Tuesday, May 7th. The company reported ($0.54) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.54). Apellis Pharmaceuticals had a negative return on equity of 160.77% and a negative net margin of 79.67%. The firm had revenue of $172.33 million for the quarter, compared to analyst estimates of $163.37 million. During the same period in the previous year, the firm earned ($1.56) earnings per share. The company’s revenue was up 284.3% compared to the same quarter last year. On average, equities analysts anticipate that Apellis Pharmaceuticals will post -1.1 EPS for the current year.

Insider Activity

In other news, insider Pascal Deschatelets sold 69,107 shares of the company’s stock in a transaction on Monday, April 8th. The stock was sold at an average price of $54.17, for a total transaction of $3,743,526.19. Following the transaction, the insider now owns 1,115,983 shares of the company’s stock, valued at approximately $60,452,799.11. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, insider Pascal Deschatelets sold 69,107 shares of the company’s stock in a transaction on Monday, April 8th. The stock was sold at an average price of $54.17, for a total transaction of $3,743,526.19. Following the transaction, the insider now owns 1,115,983 shares of the company’s stock, valued at approximately $60,452,799.11. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director A. Sinclair Dunlop sold 37,000 shares of the company’s stock in a transaction on Friday, June 21st. The shares were sold at an average price of $39.24, for a total value of $1,451,880.00. Following the transaction, the director now directly owns 136,998 shares in the company, valued at approximately $5,375,801.52. The disclosure for this sale can be found here. Insiders have sold 185,014 shares of company stock valued at $8,537,118 in the last 90 days. Insiders own 6.80% of the company’s stock.

Institutional Trading of Apellis Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. Future Financial Wealth Managment LLC purchased a new stake in Apellis Pharmaceuticals during the 1st quarter worth about $29,000. BI Asset Management Fondsmaeglerselskab A S bought a new position in Apellis Pharmaceuticals in the 1st quarter worth about $89,000. CWA Asset Management Group LLC bought a new position in Apellis Pharmaceuticals in the 4th quarter worth about $205,000. HC Advisors LLC bought a new position in Apellis Pharmaceuticals in the 4th quarter worth about $210,000. Finally, Woodward Diversified Capital LLC bought a new position in Apellis Pharmaceuticals in the 4th quarter worth about $210,000. Hedge funds and other institutional investors own 96.29% of the company’s stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).